Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. Its lead program, Elraglusib Injection, is an intravenous solution of elraglusib for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib Injection has been evaluated in a Phase I dose escalation study (Actuate-1801 Part 1) in 238 adult patients. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	5.260 $	-4.71%	66,871
13/26/13	5.520 $	-4.00%	30,212
12/26/12	5.750 $	-6.35%	95,323
09/26/09	6.140 $	-2.23%	71,140
08/26/08	6.280 $	-3.24%	62,142

Delayed Quote Nasdaq, January 15, 2026 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.520USD

Average target price

25.03USD

Spread / Average Target

+353.44%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 15/01/2026 am IST			5-day change	1st Jan Change
5.260 ^USD	-4.71%		-21.02%	-14.05%

13/01	Actuate Therapeutics Inc - Reports positive phase 2 trial data for elraglusib - SEC filing	RE
12/01	Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026	CI

Capitalization	13Cr 11Cr 10Cr 9.55Cr 18Cr 1.16TCr 19Cr 117.95Cr 46Cr 553.6Cr 48Cr 47Cr 2.03TCr	P/E ratio 2025 *	-	P/E ratio 2026 *	-
Enterprise value	13Cr 11Cr 10Cr 9.55Cr 18Cr 1.16TCr 19Cr 117.95Cr 46Cr 553.6Cr 48Cr 47Cr 2.03TCr	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	81.31%	Yield 2025 *	-	Yield 2026 *	-

13/01	Actuate Therapeutics Inc - Reports positive phase 2 trial data for elraglusib - SEC filing	RE
12/01	Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026	CI
07/01	Actuate Therapeutics Insider Sold Shares Worth $1,624,000, According to a Recent SEC Filing	MT
06/01	Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 Data	MT
06/01	Actuate Therapeutics announces positive patient outcomes from phase 1 trial	RE
06/01	Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-To-Treat Refractory Pediatric Cancers	CI
15/12	Actuate Therapeutics, Inc. Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma	CI
09/12	Certain Restricted Stock Units of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
09/12	Certain Warrants of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
09/12	Certain Options of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
09/12	Certain Common Stock of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
29/11	Actuate Therapeutics Inc enters at the market issuance sales agreement with B. Riley and Craig-Hallum - SEC filing	RE
14/11	Actuate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

12/01	Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026	AQ
06/01	Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers	AQ
18/12	Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026	AQ
15/12	Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma	AQ
30/25/30	Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP)	AQ

Actuate Therapeutics, Inc. Share Price

Equities

ACTU

US0050831009

Biotechnology & Medical Research

Valuation: Actuate Therapeutics, Inc.

Chart: Actuate Therapeutics, Inc.

Latest news: Actuate Therapeutics, Inc.

Last Transcript: Actuate Therapeutics, Inc.

Analysts' recommendations: Actuate Therapeutics, Inc.

Press Releases: Actuate Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Actuate Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	-4.71%
1 week	-21.02%
Current month	-14.05%
1 month	-30.05%
3 months	-34.98%
6 months	-14.33%
Current year	-14.05%

1 week	5.08	6.72
1 month	5.08	7.7
Current year	5.08	7.05
1 year	5.08	11.99
3 years	5.08	11.99
5 years	5.08	11.99
10 years	5.08	11.99

Manager	Title	Age	Since
Daniel Schmitt CEO	Chief Executive Officer	64	01/03/2015
Paul Lytle DFI	Director of Finance/CFO	58	01/02/2024
Steven D. Reich CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Daniel Schmitt BRD	Director/Board Member	64	01/04/2015
Aaron Fletcher CHM	Chairman	45	01/04/2015
Daniel Zabrowski BRD	Director/Board Member	66	01/03/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ACTUATE THERAPEUTICS, INC.	-4.71%	-21.02%	-34.90%	-	13Cr
ARGENX SE	-0.89%	+0.70%	+6.80%	+86.25%	4.96TCr
WUXI APPTEC CO., LTD.	-1.15%	+7.43%	+94.47%	+13.63%	4.46TCr
INSMED INCORPORATED	-0.16%	-6.63%	+137.14%	+740.41%	3.49TCr
BIONTECH SE	+1.80%	+11.24%	-4.06%	-24.77%	2.69TCr
GENMAB A/S	+4.89%	+6.38%	+44.02%	-18.56%	2.06TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.55%	+17.30%	+136.69%	-44.90%	2.11TCr
AKESO, INC.	+2.32%	+2.49%	+122.74%	+153.39%	1.42TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.00%	+5.76%	+177.12%	-	1.44TCr
SUMMIT THERAPEUTICS INC.	+5.00%	-5.41%	-2.89%	+267.71%	1.3TCr
Average	+0.46%	+1.00%	+67.71%	+146.64%	2.39TCr
Weighted average by Cap.	+0.47%	+3.02%	+72.13%	+152.92%

	2025 *	2026 *
Net sales	-	-
Net income	-	-
Net Debt	-	-